Advaxis Inc. plans to start a randomized study by the end of the year for its Listeria-based vaccine ADXS-DUAL with Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo (nivolumab) in recurrent metastatic cervical cancer, in hopes that it could serve as a registrational trial, given the small patient population and high unmet need.
Advaxis and Bristol announced their plans to collaborate on a study of squamous and non-squamous cell cervical cancer on May 30